- About Us
- Alumni Association
- Annual Reports and Financials
- Board of Directors
- CGD Europe
- Careers and Fellowships
- Contact Us
- Evaluations of CGD
- Our Funding
- Mission and Impact
- Research Data and Code Disclosure
- Staff Directory
- Support Us
- Working Groups
A New Grand Bargain to Improve the Antimicrobial Market for Human Health
June 27, 2022
While there have been high-level commitments from the World Health Assembly, the United Nations General Assembly (UNGA), the G20, and the G7 to tackle AMR, there has yet to be a fundamental change in how we purchase antimicrobials, or an international approach to improving access, fostering innovati...
Study Group on Technology, Comparative Advantage, and Development Prospects
August 30, 2018
Advances in artificial intelligence, robotics, and information and communications technology have the potential to transform a range of industries and services around the world. While the effects of these changes in OECD countries have been broadly researched, their potential impacts in the developi...
Incorporating Economics and Modelling in Global Health Goals and Guidelines
November 15, 2017
International organizations influence national-level health sector priorities by affecting how much funding is available for healthcare delivery within countries and setting limits on how that funding is used. They exert particular influence in setting disease-specific targets, developing clinical g...
Working Group on the Future of Global Health Procurement
July 31, 2017
Many low-and lower-middle-income countries currently procure a large portion of their health commodities through centralized, donor-managed procurement mechanisms, and often at subsidized prices or as donations. Over the next several decades, however, the landscape of global health procurement will ...
Drug Resistance Working Group (November 2007 – June 2010)
September 10, 2014
Value for Money: An Agenda for Global Health Funding Agencies
August 25, 2014
As international commitments become more ambitious and aid resources become increasingly constrained, global health funding agencies are seeking to improve the efficiency and impact of their investments. This growing “value for money” (VfM) agenda aims to reduce costs, increase imp...